Bausch Health Companies Inc. · TSX:BHC
Bausch Health Companies — Biovail Corp International — Corporate Update (November 2005)
10 slides from Bausch Health Companies's corporate update, Nov 4, 2005
Slide 1: Biovail Enters Into Agreement with Ortho-McNeil for Tramadol Products
Biovail Enters Into Agreement with Ortho-McNeil for Tramadol Products Nov. 3, 2005
Slide 2: Forward-looking statements
To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21€ of the Securities Exchange Act of 1934, as amended. We have
Slide 3: Link to searchable text of slide shown above
Link to searchable text of slide shown abov e
Slide 4: Supply & distribution agreement with Ortho-McNeil
« Supply & distribution agreement with Ortho-McNeil (OMI), a Johnson & Johnson company * Biovail-developed once-daily and ODT formulations of tramadol * U.S. launch under Ultram® brand names anticipated early-2006 * Ortho-McNeil, as the innovator, is the IDEAL partner * Biovail to co-promote Ultram@
Slide 5: Launch anticipated early 2006
* Launch anticipated early 2006 Biovail will manufacture and supply Ultram@® ER to OMI Biovail’s supply price range: 27.5% to 37.5% of OMI's net selling price Supply price lowest in 2006, peaks in 2007 and 2008 Supply price adjusted if/when generic formulation is launched
Slide 6: $60 million supply prepayment to Biovail upon closing
* $60 million supply prepayment to Biovail upon closing 10-year term Biovail will co-promote Ultram@®ER to women’s health specialists OMI retains option for other jurisdictions, excluding Canada and Europe Minimum performance obligations related to promotional activity
Slide 7: Link to searchable text of slide shown above
Link to searchable text of slide shown abov e
Slide 8: Link to searchable text of slide shown above
Link to searchable text of slide shown abov e
Slide 9: Ultram ER benefits from significant first-mover advantage
Slovan) Ultram® ER benefits from significant first-mover advantage = First and only once-daily tramadol to be reviewed, approved by FDA - OMI: Ideal marketing partner = Ultram@: Established, respected brand name in pain Launch anticipated early 2006 by OMI Biovail’s supply price range: 27.5% to 37.5
Slide 10: Searchable text section of graphics shown above
Searchable text section of graphics shown above [BIOVAIL logo] Biovail Enters Into Agreement with Ortho-McNeil for Tramadol Products Nov. 3, 2005 Safe Harbor Statement To the extent any statements made in this presentation contain information that is not historical, these statements are forward-look
Biovail Corp International — Corporate Update (November 2005) on 6ix